Gene therapy

Haemophilia
#Cell and gene therapy #Gene therapy #Haemophilia #University College London

Haemophilia gene therapy patients thriving a decade later

Patients who received a one-off gene therapy to treat haemophilia are still doing well up to 13 years later, finds a new study from researchers at University College London (UCL), the Royal Free Hospital and St Jude Children’s Research Hospital, Tennessee.  The study,… Read More

#Editor's Choice #News

AAV gene therapy
#AAV #Gene therapy #Genomics #Nanopore sequencing #Webinar

Improve confidence in your vector batch profiling for gene therapies

As the field of gene therapy advances, the need for fast, accurate, and scalable characterisation of adeno-associated virus (AAV) products and the plasmids used to produce them has never been greater. Join Oxford Nanopore Technologies and Plasmidsaurus on 11 June at 5pm BST for an… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

Neurones in the brain
#Alzheimer's #Cell and gene therapy #Cognitive impairment #Gene therapy #Neurology #Neuroscience #University of California San Diego

Alzheimer’s gene therapy shows promise in preserving brain function

Researchers at University of California San Diego School of Medicine have developed a gene therapy for Alzheimer’s disease (AD) that could help protect the brain from damage and preserve cognitive function. Unlike existing treatments for AD that target unhealthy protein deposits in the brain, the new approach could help address… Read More

#News

Human adenovirus
#AAV #Gene therapy #Genomics #Nanopore sequencing #Webinar

Webinar: Gain deeper insights into AAV products

As the field of gene therapy advances, the need for fast, accurate, and scalable characterisation of adeno-associated virus (AAV) products and the plasmids used to produce them has never been greater. Join Oxford Nanopore Technologies and Plasmidsaurus on 11 June at 5pm BST for an… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

Lipid nanoparticle siRNA antivirals
#Drug delivery #Gene therapy #Lipid based nanoparticle (LNP) #University of Nottingham

New cryogenic ion microscopy used to analyse lipid nanoparticles

Scientists have developed a method for analysing the structure of lipid nanoparticles that could be used to improve vaccine and drug delivery.  A team led by scientists at the University of Nottingham’s School of Pharmacy demonstrated a new cryogenic mass spectrometry approach for depth profiling frozen lipid… Read More

#News

#AAV #Gene therapy #Genomics #Nanopore sequencing #Webinar

Webinar: Genomics solutions for gene therapy development

As the field of gene therapy advances, the need for fast, accurate, and scalable characterisation of adeno-associated virus (AAV) products and the plasmids used to produce them has never been greater. Join Oxford Nanopore Technologies and Plasmidsaurus on 11 June at 5pm BST for an… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

RNA
#Collaboration #Eli Lilly #Gene therapy #Hearing Loss #RNA

Lilly and Rznomics agree $1.3 billion RNA-editing deal

Eli Lilly has entered into an agreement to develop and commercialise novel RNA-editing therapies using Rznomics' proprietary trans-splicing ribozyme platform.  Rznomics is a clinical-stage biopharmaceutical company based in South Korea focused on developing RNA-based gene therapies.  The collaboration focuses on the discovery and development of RNA-editing therapeutics for sensorineural hearing… Read More

#Business & Investment #News

#CRISPR #Gene editing #Gene therapy #Rare disease

Personalised CRISPR gene editing therapy treats rare disease

A landmark study from the Children’s Hospital of Philadelphia (CHOP) and Penn Medicine has showcased the power of a customised gene editing therapy to treat a patient with a rare metabolic disease. A child diagnosed with rare genetic disorder severe carbamoyl phosphate synthetase 1 (CPS1) deficiency was… Read More

#Editor's Choice #News

#AAV #Gene therapy #Genomics #Nanopore sequencing #Webinar

Webinar: Rapid, comprehensive AAV genomic profiling made simple

As the field of gene therapy advances, the need for fast, accurate, and scalable characterisation of adeno-associated virus (AAV) products and the plasmids used to produce them has never been greater. Join Oxford Nanopore Technologies and Plasmidsaurus on 11 June at 5pm BST for an… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

#AAV #Gene therapy #Genomics #Nanopore sequencing

What’s in your gene therapy product? Rapid, comprehensive AAV genomic profiling made simple

As the field of gene therapy advances, the need for fast, accurate, and scalable characterisation of adeno-associated virus (AAV) products and the plasmids used to produce them has never been greater. Join Oxford Nanopore Technologies and Plasmidsaurus for an expert-led webinar, hosted by DDW, showcasing new and improved genomics solutions… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#Webinars

#AI / data analytics / healthtech / informatics #Cancer research #Drug discovery #Emulate #Gene expression #Gene therapy #Interview #Metabolomics #Multi-omics #Next generation sequencing #NGS #Omics #Organ-on-a-chip #Personalised medicine #Preclinical investigations #Spatial biology

Podcast: Cutting-edge tools shaping early-stage drug discovery

This is the latest episode of the free DDW narrated podcast, titled “Cutting-edge tools shaping early-stage drug discovery”, which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “The use-case for NGS”, “Are organ-chips the future of preclinical… Read More

#News

#Gene therapy #Genetic diseases #Ophthalmology #Retinitis pigmentosa

Gene therapies for inherited retinal disorders

Christopher Doyle, PhD, Senior Director of IBC Services at WCG provides an overview of common approaches, emerging trends, and future prospects of gene therapies for inherited retinal disorders. Inherited retinal disorders (IRDs) are a group of genetically diverse conditions that lead to significant vision impairment and often culminate in complete… Read More

#Exclusive Content

#European Medicines Agency #Gene therapy #Kidney disease #Orphan drugs #Purespring Therapeutics

EMA orphan designation for IgA nephropathy gene therapy

The European Medicines Agency (EMA) has granted orphan drug designation to Purespring Therapeutics’ PS-002 in IgA nephropathy (IgAN), an autoimmune kidney disease that primarily affects young adults.  Orphan drug designation in the European Union (EU) provides incentives including market exclusivity, protocol assistance (guidance on study design and scientific evaluation) and… Read More

#News #Regulatory

Epidermolysis bullosa patient has foot bandaged
#Abeona Therapeutics #Epidermolysis bullosa #FDA #Gene therapy

Gene therapy for severe skin disease secures historic approval

The US Food and Drug Administration (FDA) has approved Abeona Therapeutics’ Zevaskyn (prademagene zamikeracel) gene-modified cellular sheets, also known as pz-cel.  Zevaskyn is an autologous cell-based gene therapy for the treatment of wounds in adult and paediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).  “Today’s approval of Zevaskyn represents a… Read More

#News #Regulatory #Trending News

Neurons
#AAV #BlackfinBio #FDA #Gene therapy #Neurology #Orphan drugs #Paediatrics #Rare disease

FDA clears gene therapy trial for rare neurological disease

The US Food and Drug Administration (FDA) has cleared BlackfinBio’s Investigational New Drug (IND) application for a Phase I/II clinical trial of novel adeno-associated virus (AAV) gene therapy, BFB-101, in children with Hereditary Spastic Paraplegia Type 47 (SPG47).  The trial will be conducted in the US at Boston Children’s Hospital… Read More

#News #Regulatory

Neurons in a brain with Alzheimer's disease
#Alzheimer's #Antibody #Gene therapy #Neuroscience #Tau protein #Voyager Therapeutics

Anti-tau antibody and gene therapy show potential in Alzheimer’s

A single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in preclinical studies.  Voyager Therapeutics will share the new data from its two preclinical programmes for Alzheimer’s disease (AD) at the 2025 International… Read More

#News